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Argyrophilic grain disease (AGD) is a common 4R-tauopathy, causing or contributing
to cognitive impairment in the elderly. AGD is characterized neuropathologically by pre-
tangles in neurons, dendritic swellings called grains, threads, thorn-shaped astrocytes,
and coiled bodies in oligodendrocytes in the limbic system. AGD has a characteristic
pattern progressively involving the entorhinal cortex, amygdala, hippocampus, dentate
gyrus, presubiculum, subiculum, hypothalamic nuclei, temporal cortex, and neocortex
and brainstem, thus suggesting that argyrophilic grain pathology is a natural model of
tau propagation. One series of WT mice was unilaterally inoculated in the hippocampus
with sarkosyl-insoluble and sarkosyl-soluble fractions from “pure” AGD at the age of
3 or 7/12 months and killed 3 or 7 months later. Abnormal hyper-phosphorylated
tau deposits were found in ipsilateral hippocampal neurons, grains (dots) in the
hippocampus, and threads, dots and coiled bodies in the fimbria, as well as the
ipsilateral and contralateral corpus callosum. The extension of lesions was wider
in animals surviving 7 months compared with those surviving 3 months. Astrocytic
inclusions were not observed at any time. Tau deposits were mainly composed of 4Rtau,
but also 3Rtau. For comparative purposes, another series of WT mice was inoculated
with sarkosyl-insoluble fractions from primary age-related tauopathy (PART), a pure
neuronal neurofibrillary tangle 3Rtau + 4Rtau tauopathy involving the deep temporal
cortex and limbic system. Abnormal hyper-phosphorylated tau deposits were found in
neurons in the ipsilateral hippocampus, coiled bodies and threads in the fimbria, and
the ipsilateral and contralateral corpus callosum, which extended with time along the
anterior-posterior axis and distant regions such as hypothalamic nuclei and nuclei of
the septum when comparing mice surviving 7 months with mice surviving 3 months.
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Astrocytic inclusions were not observed. Tau deposits were mainly composed of 4Rtau
and 3Rtau. These results show the capacity for seeding and spreading of AGD tau and
PART tau in the brain of WT mouse, and suggest that characteristics of host tau, in
addition to those of inoculated tau, are key to identifying commonalities and differences
between human tauopathies and corresponding murine models.
Keywords: argyrophilic grain disease, primary age-related tauopathy, tauopathies, tau, seeding, progression,
coiled bodies
INTRODUCTION
Argyrophilic grain disease (AGD) is a neurodegenerative
disorder morphologically characterized by the accumulation
of 4R hyper-phosphorylated tau protein in dendritic swellings
known as argyrophilic grains, neurons with pre-tangles, coiled
bodies in oligodendrocytes, and astrocytes with the morphology
of thorn-shaped astrocytes (TSAs), located predominantly in
limbic regions of the brain (Braak and Braak, 1987, 1989; Tolnay
et al., 1997; Botez et al., 1999; Togo et al., 2002; Zhukareva
et al., 2002; Tolnay and Clavaguera, 2004; Ferrer et al., 2008;
Tolnay and Probst, 2008; Tolnay and Braak, 2011; Kovacs,
2015; Ikeda et al., 2018; Rösler et al., 2019). Ballooned neurons
containing αB-crystallin are also constant in the amygdala in
AGD (Tolnay and Probst, 1998).
The frequency of AGD increases with age; it can be clinically
silent or manifested by progressive cognitive impairment and
dementia which makes it difficult to distinguish from Alzheimer’s
disease (AD) (Braak and Braak, 1989; Jellinger, 1998; Ding
et al., 2006; Rodriguez and Grinberg, 2015). Moreover, AGD is
commonly associated with AD, other tauopathies, Lewy body
diseases, and TDP-43 proteinopathy (Braak and Braak, 1989;
Ferrer et al., 2008; Josephs et al., 2008; Fujishiro et al., 2009;
Kovacs et al., 2013; Yokota et al., 2018). The majority of cases of
AGD are sporadic but a few cases have been linked to mutations
in the MAPT gene (Kovacs et al., 2008; Rönnbäck et al., 2014).
Neuropathological studies of routine series suggest that
AGD shows an archetypal pattern of progression (Saito et al.,
2004; Ferrer et al., 2008). AGD stage 1 affects the anterior
entorhinal cortex, part of the cortical and basolateral nuclei of
the amygdala, and the hypothalamic lateral tuberal nucleus; stage
2 involves a greater number of lesions and progression to the
whole entorhinal cortex, anterior CA1, transentorhinal cortex,
cortical and basolateral nuclei of the amygdala, presubiculum,
hypothalamic lateral tuberal nucleus, and dentate gyrus; stage 3
further involves CA1, perirhinal cortex, presubiculum, amygdala,
dentate gyrus, hypothalamic lateral tuberal nucleus, CA2 and
CA3, subiculum, other nuclei of the hypothalamus including
the mammillary bodies, anterior temporal cortex, insular
cortex, anterior cingulated gyrus, orbitofrontal cortex, nucleus
accumbens, and septal nuclei; and stage 4 is characterized
by further moderate-to-severe involvement of the neocortex
and brainstem (Saito et al., 2004; Ferrer et al., 2008; Tolnay
and Probst, 2008). This pattern has prompted consideration
of argyrophilic grain pathology as a natural model of tau
propagation (Clavaguera et al., 2013a; Rábano et al., 2014).
Indeed, inoculation of brain homogenates from AGD cases to the
brain of mice transgenic for wild-type human tau (line ALZ17)
leads to the capacity for abnormal tau seeding and propagation
(Clavaguera et al., 2013b, 2015). In addition to tau deposits
in neurons and threads, phospho-tau immunoreactivity is seen
in oligodendrocytes forming coiled bodies, and in astrocytes
reminiscent of TSAs, following injection of AGD homogenates
in the hippocampus and in the cerebral cortex (Clavaguera
et al., 2013a). Moreover, brain extracts from AGD patients have
the capacity to transmit tau to HEK293 cells expressing 4Rtau,
thus suggesting that prion-like tau strains can also propagate in
cultured cells (Woerman et al., 2016).
Our previous studies have shown tau seeding and spreading
following inoculation of sarkosyl-insoluble fractions from
AD, primary age-related tauopathy (PART), aging-related tau
astrogliopathy (ARTAG), progressive supranuclear palsy (PSP),
Pick’s disease (PiD), frontotemporal lobar degeneration linked to
MAPT P301L mutation, and sporadic and familial globular glial
tauopathy (GGT) into the hippocampus and corpus callosum
of WT mice (Ferrer et al., 2018, 2019, 2020a,b). The present
study is focused on the capacity for and characteristics of
seeding and propagation of phospho-tau from homogenates of
“pure” (not associated with AD or other tauopathies) AGD
cases in the hippocampus of WT mice. For comparative
purposes, another set of mice was unilaterally inoculated in
the hippocampus with sakosyl-insoluble and -soluble fractions
of PART, a 3Rtau + 4Rtau pure neuronal tauopathy with
neurofibrillary tangles (Crary et al., 2014), that is considered part
of AD (Duyckaerts et al., 2015).
MATERIALS AND METHODS
Human Brain Samples
Brain samples of the hippocampus were obtained from the
Institute of Neuropathology Brain Bank, Bellvitge University
Hospital, following the guidelines of the Spanish legislation
on this matter (Real Decreto Biobancos 1716/2011), and
the approval of the local ethics committee of the Bellvitge
University Hospital (Hospitalet de Llobregat, Barcelona, Spain).
The agonal state was short with no evidence of acidosis or
prolonged hypoxia; the pH of each brain was between 6.8
and 7. At the time of autopsy, one hemisphere was fixed
in paraformaldehyde for no less than 3 weeks and selected
brain sections were embedded in paraffin; de-waxed paraffin
sections, 4 microns thick, were processed with neuropathological
and immunohistochemical methods as detailed elsewhere
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(Ferrer, 2014). The other hemisphere was cut into coronal
sections 1 mm thick, and selected brain regions were dissected,
immediately frozen at −80◦C, put on labeled plastic bags, and
stored at −80◦C until use; the rest of the coronal sections were
frozen and stored at −80◦C (Ferrer, 2014). Four AGD cases
were used for this study, all of them men, aged 63, 67, 74,
and 75 years old. The four cases were categorized as stage 3 of
AGD. Two cases had pre-tangles, threads and grains but not
NFTs; one of them had NFT stage I and another NFT stage
II following Braak and Braak staging of AD-related pathology.
β-amyloid deposits were absent in every case. Other AGD cases
from our series with marked AD pathology were excluded from
the present study. AGD cases with other tauopathies such as
PSP and corticobasal degeneration, and cases with concomitant
TDP-43 proteinopathy or with Lewy body disease, were excluded.
This selection permitted a reasonable approach to the study of
“pure” AGD pathology.
Two PART cases (one man aged 68 and one woman aged
72) were selected on the basis of pure neurofibrillary tangle
(NFT) pathology with no accompanying tauopathy and without
β-amyloid deposits (Crary et al., 2014). NFT burden in PART
cases was categorized as stage IV according to Braak and Braak
modified for paraffin sections (Braak and Braak, 1991; Braak
et al., 2006). The subjects did not have apparent neurological
deficits and the diagnosis was made at the post-mortem
neuropathological examination.
One case (a 65-year-old man) with no neurological disease and
with no lesions on neuropathological examination, and one case
of AD stage V-VI/C (one woman aged 82) were used as negative
and positive controls, respectively.
Western Blotting
Frozen samples of the hippocampus from the four AGD and the
two PART cases were processed in parallel with one AD case
(Braak and Braak stage V–VI/C) and one case with no lesions.
Frozen samples of about 1 g were lysed in 10 volumes (w/v) with
cold suspension buffer (10 mM Tris-HCl, pH 7.4, 0.8 M NaCl,
1 mM EGTA) supplemented with 10% sucrose, protease, and
phosphatase inhibitors (Roche, GE). The homogenates were first
centrifuged at 20,000 × g for 20 min (Ultracentrifuge Beckman
with 70Ti rotor) and the supernatant (S1) was saved. The
pellet was re-homogenized in five volumes of homogenization
buffer and re-centrifuged at 20,000 × g for 20 min. The
two supernatants (S1 + S2) were then mixed and incubated
with 0.1% N-lauroylsarkosynate (sarkosyl) for 1 h at room
temperature while being shaken. Samples were then centrifuged
at 100,000 × g for 1 h. Sarkosyl-insoluble pellets (P3) were re-
suspended (0.2 ml/g) in 50 mM Tris–HCl (pH 7.4). Protein
concentrations were quantified with the bicinchoninic acid assay
(BCA) assay (Pierce, Waltham, MA, United States).
Sarkosyl-insoluble and sarkosyl-soluble fractions were
processed for western blotting.
Samples were mixed with loading sample buffer and
heated at 95◦C for 5 min. 60 µg of protein was separated
by electrophoresis in SDS-PAGE gels and transferred to
nitrocellulose membranes (200 mA per membrane, 90 min).
The membranes were blocked for 1 h at room temperature
with 5% non-fat milk in TBS containing 0.2% Tween and
were then incubated with the primary phospho-specific antibody
anti-tau Ser422 (diluted 1:1,000; Thermo Fisher Scientific
(Waltham, MA, United States). After washing with TBS-T,
blots were incubated with the appropriate secondary antibody
(anti-rabbit IgG conjugated with horseradish peroxidase diluted
at 1:2,000, Agilent, United States) for 45 min at room
temperature. Immune complexes were revealed by incubating the
membranes with chemiluminescence reagent (Amersham, GE
Healthcare, Life Sciences, Buckinghamshire, United Kingdom)
(Ferrer et al., 2018).
Thioflavin T (ThT) Amyloid Quantification
Assay
ThT stock solution was prepared at 2.5 mM (dissolved in 10 mM
phosphate buffer, 150 mM NaCl, pH 7.0) and preserved in single-
aliquot at−80◦C. The ThT assay was performed by dissolving 0.2
µL of sarkosyl-insoluble fraction in 0.2 mL of freshly prepared
ThT (final concentration 30 µM) followed by quantification using
an absorbance/excitation (445/485) microplate reader (Tecan
Infinite M200Pro, Männedorf, Switzerland) in 96 flat bottom
polystyrol plates (Nunclor, Thermo Fisher Scientific, GE). Plates
were prepared and incubated at 37◦C. Readings were taken each
hour over the course of 15–16 h.
Animals and Brain Inoculation
Wild-type C57BL/6 mice from our colony were used. All
animal procedures were carried out following the guidelines
of the European Communities Council Directive 2010/63/EU
and with the approval of the local ethical committee (C.E.E.A:
Comitè Ètic d’Experimentació Animal; University of Barcelona,
Spain; ref. 426/18).
One series of mice was inoculated with sarkosyl-insoluble
fractions of a mixture of the two AGD cases with no NFTs, in
which western blotting of sarkosyl-insoluble fractions showed
only the bands of 68 and 64 kDa typical of 4Rtaupathies. The
animals were inoculated at the age of 3 months and killed at the
age of 6 months (n = 2, survival 3 months); 3 months and killed
at the age of 10 months (n = 1, survival 7 months); 7 months and
killed at the age of 10 months (n = 2, survival 3 months); and
12 months and killed at the age of 19 months (n = 2, survival
7 months). Two mice were inoculated with a mixture of sarkosyl-
soluble fractions at the age of 7 months and killed at the age
of 10 months (n = 2, survival 3 months); and one mouse was
inoculated with vehicle (50 mM Tris-HCl, pH 7.4) at the age of
3 months and killed at the age of 10 months (survival 7 months).
Three additional inoculated mice died shortly after anesthesia
and were not included in the study.
For comparative purposes, another series of mice was
inoculated with sarkosyl-insoluble fractions of two PART cases
at the age of 3 months and killed at the age of 10 months (n = 3,
survival 7 months); 7 months and killed at the age of 10 months
(n = 3, survival 3 months); 12 months and killed at 19 months
(n = 4, survival 7 months). Finally, mice were inoculated with
PART sarkosyl-soluble fractions at the age of 7 months and killed
at the age of 10 months (n = 2, 3 months survival); and with
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control brain homogenates at the age of 3 or 7 months and
killed at the age of 10 months (n = 2, 7 and 3 months survival,
respectively). The total number of available mice considering the
two series was 24.
Mice were deeply anesthetized by intra-peritoneal
ketamin/xylazine/buprenorphine cocktail injection and placed in
a stereotaxic frame after assuring lack of reflexes. Intra-cerebral
injections were administered using a Hamilton syringe; the
coordinates for hippocampal injections were −1.9 mm AP;
−1.4 mm ML relative to Bregma (interaural 1.8 mm), and
−1.5 mm DV from the dural surface (Paxinos and Franklin,
2019). A volume of 1.5 µL was injected at a rate of 0.05 µL/min.
The syringe was withdrawn slowly over a period of 10 min to
avoid leakage of the inoculum. Following surgery, the animals
were kept in a warm blanket and monitored until they recovered
from the anesthesia. Carprofen analgesia was administered
immediately after surgery and once a day during the next 2
consecutive days. Animals were housed individually with full
access to food and water.
Tissue Processing
Animals were killed under anesthesia and the brains were
rapidly fixed with 4% paraformaldehyde in phosphate buffer,
and embedded in paraffin. Consecutive serial sections 4 µm
thick were obtained with a sliding microtome. De-waxed sections
were stained with hematoxylin and eosin, Congo Red, and
Thioflavin T, or processed for immunohistochemistry using the
antibodies anti-phospho-tau Thr181, anti-phospho-tau Ser262,
Ser422, AT8 (Ser202/Thr205), PHF1(Ser396/Ser404) (donation
of Dr. Peter Davies, Albert Einstein College of Medicine,
Bronx, NY, United States), anti-4Rtau, anti-3Rtau, and tau-C3
(tau truncated at aspartic acid 421), in addition to GFAP for
reactive astrocytes and Iba1 for microglia. The characteristics
of the antibodies are shown in Table 1. Following incubation
with the primary antibody, the sections were incubated with
EnVision + system peroxidase for 30 min at room temperature.
The peroxidase reaction was visualized with diaminobenzidine
and H2O2. Control of the immunostaining included omission
of the primary antibody; no signal was obtained following
incubation with only the secondary antibody. The specificity of
3Rtau and 4Rtau antibodies in mice was tested in coronal sections
of the brain, cerebellum, and brainstem of P301S transgenic
mice aged 8–9 months old (López-González et al., 2015). Tau-
immunoreactive inclusions in animals expressing mutant human
4Rtau were stained with anti-4Rtau antibodies but they were
negative with anti-3Rtau antibodies.
Double-labeling immunofluorescence was carried out on de-
waxed sections, 4 µm thick. The sections were boiled in citrate
buffer to enhance antigenicity and blocked for 30 min at
room temperature with 10% fetal bovine serum diluted in 0.1
M phosphate-buffered saline (PBS). The sections were stained
with a saturated solution of Sudan black B (Merck, DE) for
15 min to block autofluorescence of putative lipofuscin granules
present in cell bodies, and then rinsed in 70% ethanol and
washed in distilled water. Then, the sections were incubated
at 4◦C overnight with combinations of AT8 and one of
the following primary antibodies: GFAP, Iba-1, Olig2, and





4Rtau Monoclonal 1:50 Merck-Millipore Billerica, MA,
United States


















AT8 (Ser202/Thr205) Monoclonal 1:50 Innogenetics Ghent, BE
PHF1(Ser396/Ser404) Monoclonal 1:20 Dr. Peter Davies New York,
United States










1:500 Dako Glostrup, DK
Iba1 Rabbit
polyclonal






NeuN Monoclonal 1:100 Merck-Millipore Billerica, MA,
United States
p38-P (Thr180-Tyr182). Other sections were immunostained
with anti-phospho-tauThr181 and anti-NeuN (Table 1). After
washing, the sections were incubated with Alexa488 or Alexa546
fluorescence secondary antibodies against the corresponding
host species. Nuclei were stained with DRAQ5TM. Then
the sections were mounted in Immuno-FluoreTM mounting
medium (MP Biomedicals, CA, United States), sealed, and
dried overnight. Sections were examined with a Leica TCS-SL
confocal microscope.
In situ end-labeling of nuclear DNA fragmentation
(ApoptTagTM peroxidase in situ apoptosis detection kit,
Merck, GE) was used to visualize apoptotic cells. The brains
of newborn irradiated rats (2Gys) with a survival time of 24 h
were fixed with paraformaldehyde and embedded in paraffin;
de-waxed sections were processed in parallel with tissue samples
from inoculated mice and used as positive controls of apoptosis.
Semi-Quantitative Studies
Since lesions in mice inoculated with sarkosyl-insoluble fractions
of AGD surviving 3 and 7 months were similar, and the same
occurred following inoculation of PART (see later), the total
number of mice for each time of survival was considered for
semi-quantitative studies as follows: AGD 3 months, n = 4, AGD
7 months, n = 3; PART 3 months, n = 2, PART, 7 months n = 7.
Quantification of neurons and oligodendrocytes was made in
an area of 0.35 µm2 in affected regions in every case. Symbols
indicate the average number of labeled cells: neurons: –:0, #:
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1, ##: 2–3; ###: >3; oligodendrocytes: –: 0, φ: 1–3, φφ: 4–
7, φφφ: >7. Regarding grains, threads and dots, values were
expressed as –:0,+: mild;++: moderate; and+++: abundant.
Quantitative Studies
The number of neurons in the hippocampus, oligodendrocytes
in the ipsilateral corpus callosum, and oligodendrocytes in the
contralateral corpus callosum was counted in three different fields
of 0.035 µm2 in affected regions per mouse at the different
survival times (3 and 7 months) in the four groups of mice (AGD
and PART). Counts were compared with two-way analysis of
variance (ANOVA) followed by Tukey’s post-hoc test using SPSS
software. Differences were considered statistically significant at
∗∗P < 0.01 and ∗∗∗P < 0.001 compared with AGD 3 months
group; $$P < 0.01 and $$$P < 0.001 compared with AGD
7 months group; and ###P < 0.001 compared with PART
3 months group. Comparison between values of oligodendrocytes
in ipsilateral (ipsi) and contralateral (contr) corpus callosum
within the same PHFs type and incubation time were assessed
(comparison of two regions at the same period of time) using
T-student test and SPSS software. Differences were considered
statistically significant at xxP < 0.001 compared with AGD
3 months oligo. Ipsi group; &&&P < 0.001 compared with AGD
7 months oligo. Ipsi group; ˆˆˆP < 0.001 compared with PART
3 months oligo ipsi group; and +++P < 0.001 compared with
PART 7 months oligo ipsi group. Outliers were detected using
the GraphPad software QuickCalcs (P < 0.05). Statistical analysis
and graphic design were performed with GraphPad Prism version
5.01 (La Jolla, CA, United States).
RESULTS
AGD in the Human Hippocampal
Complex
The four cases were categorized as stage 3 of AGD. Two cases
had pre-tangles, threads, and grains, but not NFTs. The other two
cases had, in addition, some NFTs in the entorhinal cortex and
very few in the hippocampus.
Pre-tangles were localized in the pre-subiculum, subiculum,
CA2, and CA3 areas of the hippocampus, and granule cells in the
dentate gyrus. Large numbers of grains were localized in the pre-
subiculum (in addition to the entorhinal and trans-entorhinal
cortices), and CA1 region of the hippocampus. Threads, which
were characterized as fine neuritic processes, were present in the
same areas as grains, and in the white matter of the hippocampus
and entorhinal region.
Oligodendroglial inclusions, mainly with the morphology of
coiled bodies, were found in the hippocampal white matter. TSAs
were found in the periventricular white matter, and sparsely in
the white matter of the inner region of the temporal lobe.
Neuronal, astrocytic, and oligodendroglial inclusions, as
well as grains and threads, were labeled with anti-phospho-
tau antibodies Thr181, Ser262, Ser422, AT8, and PHF1.
All these deposits were positive with ant-4Rtau antibodies
and negative with anti-3Rtau antibodies (excepting very few
oligodendrocytes) (Figure 1).
Tau-C3 immunoreactivity was restricted to NFTs and
isolated coiled bodies.
Western blotting of sarkosyl-insoluble fractions processed
with anti-phospho-tau Ser422 revealed two bands of 68 and 64
kDa, and a weak band of about 37 kDa in AGD cases. This pattern
was different from that seen in one AD stage V-VI/C processed in
parallel which was characterized by three bands of 68, 64, and 60
kDa, together with several bands of about 50 kDa, several bands
between 30 and 40 kDa, and lower bands of truncated tau at
the C-terminal, one of which was about 20 kDa, in addition to
oligomeric species of higher molecular weight (Figure 2A). The
same pattern was observed in all four cases, although a lower
band of truncated tau was noted in the two cases categorized as
AGD plus NFT stage II after long exposure (30 min). Incubation
of sarkosyl-insoluble fraction with thioflavin showed moderately
increased fluorescence with time (Figure 2B).
PART in the Human Hippocampal
Complex
PART cases were characterized by numerous NFTs in the
entorhinal, transentorhinal cortex, presubiculum, subiculum,
hippocampus (with preservation of the dentate gyrus), and
temporal cortex. Threads were also abundant in these regions, but
dystrophic neurites were absent. No tau deposits were found in
astrocytes or oligodendrocytes. The morphology and distribution
of NFTs corresponded to stage IV of Braak and Braak, linked to
AD pathology. β-amyloid deposits were absent.
NFTs were identified by their typical flame-like morphology
in pyramidal neurons which were composed of 4Rtau and 3Rtau,
and stained with several specific anti-phospho-tau antibodies:
Thr181, Ser262, Ser422, AT8, and PHF1. NFTs were also positive
with antibody tau-C3 which is raised against truncated tau at
aspartic acid 421. This is exactly the same profile seen in AD
(Ferrer et al., 2013).
As in AD, PART cases were characterized by three bands of 68,
64, and 60 kDa, and several lower bands of 50 kDa and between 30
and 40 kDa, together with strong lower bands stained with anti-
tauSer422 indicating truncated tau at the C-terminal. Oligomeric
species of higher molecular weight wee manifested as smear. This
pattern is typical of 4Rtau + 3Rtau tauopathies and identical to
that seen in AD (Figure 2A).
ThT amyloid quantification assay of sarkosyl-insoluble
fractions revealed positive curves of amyloid fibrils. Interestingly,
fluorescence appeared earlier and the intensity was higher in
PART than in AGD (Figure 2C).
AGD Inoculation in the Hippocampus of
WT Mice
A mixture of sarkosyl-insoluble fractions from the two cases
without associated NFT pathology was inoculated into the
hippocampus of WT mice at the age of 3 or 7 months. Mice
were killed, respectively, at the age of 6 or 10 months (3 months
of survival; n = 2 for every condition). Inoculation resulted
in the deposition of hyper-phosphorylated tau in neurons
of the CA1 region of the hippocampus and dentate gyrus,
threads in the fimbria and corpus callosum, oligodendoglial
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FIGURE 1 | Characteristics of tau deposits in AGD. Hyper-phosphorylated tau deposits are seen in the CA1 region of the hippocampus (CA1: A), subiculum (subic:
B,F,J,M,N), entorhinal cortex (EC: C), white matter of the hippocampus (WM: E,H,K), and periventricular region of the temporal horn (perventr: F,I,L). Grains are
identified as small round, lobulated, or comma-shaped deposits in the neuropil (A–C,D,G,J). Grains are accompanied by pre-tangles in neurons (C,D,G,J), and,
rarely, by neurons with dense granular inclusions (D). In addition, oligodendroglial deposits form coiled bodies and cytoplasmic inclusions around the nucleus
(E,H,K). Thorn-shaped astrocytes (TSAs) are common in the periventricular white matter (F,I,L). All these deposits are stained with AT8 antibodies (A–F), PHF1
(G–I), and anti-P-tau Ser262 (J–L). Grains and pre-tangles are composed of 4Rtau (M,N) and do not contain 3Rtau (O). Paraffin sections, processed for
immunohistochemistry, and slightly counterstained with hematoxylin; (A,B), bar = 55 µm; (D–O), bar = 30 µm.
deposits in the fimbria and ipsilateral corpus callosum, and
grains (dots) in the dentate gyrus, fimbria, and corpus
callosum. Neuronal tau deposition consisted of diffuse or fine
granular deposits; neurofibrillary tangles were not seen in any
case at any time. Oligodendroglial tau aggregates had the
morphology of perinuclear deposits or of coiled bodies. Deposits
were immunostained with anti-phospho-tau antibodies raised
against single specific phospho-tau sites Thr181 and Ser262,
double-phosphorylated sites as revealed with antibodies AT8
(Ser202/Thr205), and PHF1 (Ser396/Ser404); and with antibodies
raised against 4Rtau and 3Rtau (Figure 3). Immunoreactivity to
tau-C3 was largely negative excepting a few grains and threads
in the corpus callosum. Mice inoculated at the age of 3 or
12 months, and killed at the age of 10 or 19 months (7 months
of survival; n = 1 and n = 2, respectively), showed, in addition to
the previous deposits, an extension of lesions to the contralateral
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FIGURE 2 | Characteristics of sarkosyl-insoluble fractions. Western blotting processed with anti-phospho-tau Ser422 (P-tau Ser422) in PART stage IV and AD
stages V–VI reveals three bands of 68, 64, and 60 kDa, and upper oligomeric smears, in addition to several bands of about 50 kDa, between 30 and 40 kDa, and
lower bands of truncated tau at the C-terminal, one of them of about 20 kDa. In contrast, “pure” AGD reveals two bands of 68 and 64 kDa, and a weak band of
about 37 kDa (A). Thioflavin T incubation of sarkosyl-insoluble fractions shows slightly increased fluorescence with time indicating moderate fibril formation in AGD
up to 2,500 au (B), and rapid and higher fluorescence in PART reaching about 7,500 au up to 15 h of incubation (C).
corpus callosum characterized by threads, dots, and coiled bodies
(Figure 3). No tau deposits were seen in other brain regions.
No differences were seen between the animals inoculated Tau
deposits were negative with Congo Red, and did not show
fluorescence with thioflavin T. All the animals inoculated with
sarkosyl-insoluble fractions showed tau deposits.
Similar changes were seen in mice surviving 3 or 7 months
despite the age of inoculation.
WT Mice Inoculated With
Sarkosyl-Insoluble Fractions From PART
Sarkosyl-insoluble fractions of two PART cases were unilaterally
inoculated in the hippocampus at the age of 7 months and
killed at the age of 10 months (3 months survival); 3 months
and killed at the age of 10 months or at the age of 12 months
and killed at the age of 19 months (7 months survival). Mice
with survival of 3 months showed tau deposits in the ipsilateral
hippocampus, fimbria, and ipsilateral corpus callosum extending
along the anterior-posterior axis. Mice surviving 7 months,
independently of the age of inoculation, showed, in addition
to the previous regions, major extension along the anterior-
posterior axis, together with tau deposits in the middle and
contralateral corpus callosum, the ipsilateral periventricular
hypothalamus, and septal nuclei. Tau deposits were found in
neurons, threads, and oligodendroglial cells (mainly round and
coiled bodies) which were stained with specific anti-phospho
tau antibodies Thr181 and Ser262, double-phosphorylated sites
as revealed with antibodies AT8 (Ser202/Thr205) and PHF1
(Ser396/Ser404), and with antibodies raised against 4Rtau and
3Rtau (Figure 4). Immunoreactivity to tau-C3 was largely
negative excepting a few threads in the corpus callosum. Tau
deposits were negative with Congo Red and they did not show
fluorescence with thioflavin T.
Mice inoculated with sarkosyl-soluble fractions and
those inoculated with control brain homogenates did not
show tau deposits.
Similar changes were seen in mice surviving 3 or 7 months
despite the age of inoculation. Therefore, the distribution of
tau-immunoreactive deposits following inoculation of PART
sarkosyl-insoluble fractions with survival times of 3 and 7 months
are shown in Figure 5, together with the distribution of deposits
of AGD to facilitate comparison. Semi-quantitative studies are
summarized in Table 2.
To analyze in more detail differences in the number of
phospho-tau-containing neurons in the hippocampus in the two
groups of mice inoculated with sarkosyl-insoluble fractions of
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FIGURE 3 | Hyper-phosphorylated tau-containing cells and threads following unilateral hippocampal injection of sarkosyl-insoluble fractions from AGD in WT mice
inoculated at 7 months and killed at the age of 10 months (3 months of survival) (A,B); inoculated at the age of 3 months and killed at the age of 6 months (3 months
survival) (C); inoculated at the age of 12 months and killed at the age of 19 months (7 months survival) (D–F); and inoculated at the age of 3 months and killed at the
age of 10 months (survival 7 months) (E–H). Neurons in the ipsilateral hippocampus contain granular hyper-phosphorylated tau deposits as revealed with the AT8
antibody without morphological features of tangles (A); these deposits are stained with antibodies against 4Rtau and 3Rtau (G,H). Grains (dots) in CA1 region of the
hippocampus, dentate gyrus, fimbria, and corpus callosum are recognized with the antibody AT8 (B,C,E,F), anti P-tau Ser262 (D), and antibodies against 4Rtau and
3Rtau (G–I) (thin arrows). Threads and coiled bodies containing hyper-phosphorylated tau are seen in the ipsilateral and contralateral corpus callosum in mice
surviving 7 months after inoculation. Paraffin sections slightly counterstained with hematoxylin. CA1, region of the hippocampus; DG, dentate gyrus; fimbr, fimbria;
ipsi contr CC, ipsi- and contralateral corpus callosum; (A–F), bar = 25 µm; (G–I), bar = 25 µm. Grains, coiled bodies and grains, insets in (A,E,H), respectively,
bar = 7.5 µm.
AGD and PART with different incubation times, we performed
a statistical study using a two-way ANOVA test followed by
Tukey’s post-hoc test. Two-way ANOVA did not reveal significant
interactions between the type of the inoculums (AGD or PART)
and the survival time [F(1, 44) = 0.31, p = 0.57]. Subsequent
Tukey’s post-hoc test showed significant differences between
group AGD 3 months compared with group PART 3 months
(P = 0.003), and group PART 7 months (P = 0.001), but
not with the group AGD 7 months. Mice AGD 7 months
showed reduced number of positive neurons when compared
with mice PART 3 months (P = 0.005) and PART 7 months
(P = 0.003). Regarding the number of oligodendroglial cells in
the ipsilateral corpus callosum between groups, two-way ANOVA
revealed a significant interaction between the inoculated PHF
type and the incubation time in phosphor-tau-immunoractive
oligodendroglial cells [F(1, 43) = 10.41, p = 0.0024]. Differences
were significant when comparing AGD and PART (PHF type)
[F(1, 43) = 124.4 p < 0.0001] and the survival time (3 vs.
7 months) [F(1, 43) = 6.19, p = 0.017]. Post-hoc test showed
significant increase in phospho-tau containing oligodendroglial
cells in the ipsilateral corpus callosum in AGD 7 months
(P = 0.001), PART 3 months (P = 0.000), and PART 7 months
(P = 0.000) when compared with AGD 3 months. Similarly,
significant increase in the number of phospho-tau containing
oligodendrocytes was noticed in PART 3 months (P = 0.000)
and PART 7 months (P = 0.000) when compared with AGD
7 months. Regarding phospho-tau containing oligodendroglial
cells in the contralateral corpus callosum, two-way ANOVA
revealed significant interaction between the type of inoculums
(AGD and PART) and the survival time [F(1, 47) = 21.25,
p < 0.0001]. Significant differences were found in relation
with the effects of the inoculums (AGD or PART) [F(1,
47) = 21.25 p < 0.0001] and the survival time (3 or 7 months)
[F(1, 47) = 87.72, p < 0.0001]. Tukey’s post-hoc test revealed
significant increased numbers of phospho-tau immunoreactive
oligodendroglial cells in contralateral corpus callosum in mice
of the groups AGD 7 months (P = 0.004) and PART
7 months (P = 0.000) when compared with mice of the AGD
3 months group. Following the same trend, increased numbers
of phospho-tau containing oligodendrocytes in the contralateral
corpus callosum was seen in the groups AGD 7 months
and PART 7 months when compared with PART 3 months
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FIGURE 4 | Hyper-phosphorylated tau-containing cells and threads following unilateral intra-hippocampal injection of sarkosyl-insoluble fractions from PART into WT
mice at the age of 7 months and killed at the age of 10 months (3 months survival) (A,C); 3 months and killed at the age of 10 months (C,D–F); and at the age of
12 months and killed at the age of 19 months (7 months survival) (G–J). Tau deposits in neurons, independently of the survival time, show granular deposits in the
cytoplasm, and occasional denser inclusions with no similarities with tangles (A,B). Threads and coiled bodies are abundant in the fimbria and corpus callosum
(C–F). Individual neurons, threads and oligodendrocytes in inoculated mice are stained with anti-4Rtau (G,H) and anti-3Rtau (I,J) antibodies. Paraffin sections
slightly counterstained with hematoxylin. CA1, region of the hippocampus; fimbr, fimbria; ipsi contr CC, ipsi- and contralateral corpus callosum; (A–F), bar = 50 µm;
(G–J), bar = 50 µm.
(P = 0.016 and P = 0.000, respectively). These values show
that the number of labeled neurons in the hippocampus, and
oligodendroglial cells in the ipsilateral and contralateral callosum
was significantly higher in mice inoculated with PART sarkosyl-
insoluble fractions when compared with mice inoculatyed with
AGD fractions (Figure 6).
Finally, the number of phospho-tau-positive oligodendrocytes
in the ipsilateral corpus callosum was compared with the number
of phospho-tau-positive oligodendrocytes in the contralateral
corpus callosum at the same survival time in every one of the four
groups. Significant differences were seen between the ipsilateral
corpus callosum and the contralateral corpus callosum in mice
AGD 3 months (P = 0.000); AGD 7 months P = 0.000); PART
3 months (P = 0.000); and PART 7 months (P = 0.000). These
values indicated significant progression of phospho-tau deposits
in oligodendrocytes in the contralateral corpus callosum with
time after inoculation (Figure 6).
In situ end-labeling of nuclear fragmentation was negative
in mice inoculated with sarkosyl-insoluble fractions from
AGD and PART processed in parallel with brain sections of
newborn irradiated rats killed 24 h after irradiation (2Gy)
(data not shown).
No hyper-phosphorylated tau deposition occurred in mice
inoculated with sarkosyl-soluble fractions or with vehicle alone
(data not shown). 4Rtau and 3Rtau deposits were also absent in
these mice used as controls.
Double-Labeling Immunofluorescence
and Confocal Microscopy
Localization of phospho-tau in neurons and oligodendrocytes
in AGD-inoculated mice was identified with double-labeling
immunofluorescence with anti-phospho-tau antibodies in
combination with NeuN and Olig2 antibodies, respectively
(Figures 7A–C). Antibodies anti-p38-P (Thr180-Tyr182)
revealed co-localization with phospho-tau (AT8) in the
majority of grains or dots (Figure 7D), as well as in pre-
tangles and coiled bodies, as detailed in other tauopathies
(Ferrer et al., 2018, 2019, 2020a).
Double-labeling immunofluorescence to GFAP and
Iba1, and to AT8, confirmed the absence of phospho-tau
deposits in astrocytes and microglia, respectively, at all times
during the study.
Similar features regarding neurons and glial cells
were assessed in PART-inoculated mice using double-
labeling immunofluorescence and confocal microscopy.
In addition to neurons, oligodendrocytes and threads
were easily visualized in the corpus callosum (Figure 7E).
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FIGURE 5 | Schematic representation of phospho-tau-immunoreactive deposits (red dots), as revealed with the AT8 antibody, following unilateral inoculation of
sarkosyl-insoluble fractions from AGD and PART into the hippocampus of WT mice with survival times of 3 and 7 months. Mice inoculated with AGD and killed
3 months after inoculation show tau deposits restricted to the ipsilateral hemisphere, whereas mice inoculated with PART and killed after 3 months show wider
distribution of tau deposits along the anterior-posterior axis although restricted to the same hemisphere. Mice inoculated with AGD and killed 7 months later have, in
addition, tau deposits along the contralateral corpus callosum, whereas mice inoculated with PART and killed at 7 months post-inoculation show, in addition to the
previous regions, further extension along the anterior-posterior axis, deposits in distal projections such as the periventricular hypothalamus and septal nuclei, and
abundant deposits in the contralateral corpus callosum. Maps obtained from the atlas of Paxinos and Franklin. Red dots simply represent the distribution of lesions;
no attempt is made to distinguish between deposits in neurons, oligodendrocytes, threads and dots, and quantify the numbers or densities of each one of these
lesions.
Frontiers in Molecular Neuroscience | www.frontiersin.org 10 June 2020 | Volume 13 | Article 101
fnmol-13-00101 June 22, 2020 Time: 17:58 # 11
Ferrer et al. AGD Seeding and Spreading
TABLE 2 | Semi-quantitative representation of lesions following inoculation of sarkosyl-insoluble fractions of AGD and PART at survival times of 3 months (AGD, n = 4;
PART, n = 2) and 7 months (AGD, n = 3; PART, n = 7).
Hip neur/gr fim olig/thr cc ips olig/thr/dots cc contr olig/thr/dots Ant/post axis Other distant regions
AGD 3 months ##/+ φ/++ φ/++/+ – – –
AGD 7 months ##/+ φφ/++ φφ/+++/++ φ/++/+ + –
PART 3 monts ###/– φφφ/++ φφφ/++/+ – ++ –
PART 7 months ###/– φφ/++ φφφ/+++/++ φφφ/+++/++ +++ §§
Hip, hippocampus; fim, fimbria; cc ip and contr, corpus callosum ipsilateral and contralateral; ant/post axis, extension along the anterior/posterior axis; other distant
regions include nuclei of the hypothalamus and septal nuclei. Symbols per area of 0.035 µm2; neurons: –: 0, #: 1, ##: 2–3; ###: >3; oligodendrocytes: –: 0, : φ1–3, φφ:
4–7, φφφ: >7; grains, threads and dots: –:0, +: mild, ++: moderate, +++: abundant; other distant regions (hypothalamus and septal nuclei) –: no; §§: yes.
FIGURE 6 | Numbers of neurons in the hippocampus, oligodendrocytes in the ipsilateral corpus callosum, and oligodendrocytes in the contralateral corpus in the
four groups of mice inoculated with sarkosyl-insoluble fractions of AGD and PART with 3 months and 7 months of survival. Counts were compared with two-way
analysis of variance (ANOVA) followed by Tukey post-test using SPSS software. Differences are considered statistically significant at **P < 0.01 and ***P < 0.001
compared with AGD 3 months; $P < 0.05, $$P < 0.01, and $$$P < 0.001 compared with AGD 7 months; and ###P < 0.001 compared with PART 3 months.
Comparison between values of oligodendrocytes in ipsilateral (ipsi) and contralateral (contr) corpus callosum was assessed using T-student test and SPSS software.
Differences are considered statistically significant at xxxP < 0.001 compared with AGD 3 months ipsi; &&&P < 0.001 compared with AGD 7 months ipsi; ˆˆˆP < 0.001
compared with PART 3 months ipsi; and +++P < 0.001 compared with PART 7 months ipsi.
As for AGD, no astrocytes or microglia contained
phospho-tau deposits.
DISCUSSION
Tau seeding and spreading occur following unilateral inoculation
of sarkosyl-insoluble fractions from AD, PART, ARTAG, PSP,
PiD, FTLD linked to MAPT P301L mutation, and GGT in the
hippocampus of WT mice using the protocol utilized in the
present study (Ferrer et al., 2018, 2019, 2020a,b). Neurons and
oligodendrocytes are the main targets of tau spreading, which
progresses through synaptically connected areas, and along tracts
such as the corpus callosum to reach the contralateral hemisphere
in those settings. The present results show a similar pattern
of tau seeding and spreading following unilateral inoculation
of sarkosyl-insoluble fractions from homogenates of AGD
cases without concomitant tauopathy, and more particularly
without NFTs, in the hippocampus of WT mice. Neurons
and oligodendrocytes are the main targets; in addition, grains
(dots) and threads containing phospho-tau are present in the
hippocampus and in the corpus callosum. The morphological
characteristics of tau deposits in neurons, as revealed with
phospho-specific anti-tau antibodies, are similar to those seen
in human AGD cases bearing only pre-tangles; threads and dots
are also similar to those seen in AGD, but their presence in
the corpus callosum indicates that most “grains” in inoculated
mice are not located in dendrites, in contrast to the ordinary
dendritic localization of grains in AGD (Ferrer et al., 2008).
Therefore, what we call grains in AGD-inoculated mice are
probably small aggregates of phospho-tau in neuronal processes
other than dendrites. Coiled bodies in AGD-inoculated mice
are the counterparts of coiled bodies in AGD. Yet astrocytes
do not contain phospho-tau in inoculated mice at the survival
times (3 and 7 months) assessed in the present study, in contrast
with the presence of TSAs in AGD. The characteristics of
tau as revealed by immunohistochemistry are similar in AGD
and in AGD-inoculated WT mice. Of note, the presence of
P-tauSer262 in the inclusions a phosphorylation is also seen in
AGD (Ferrer et al., 2002). Co-localization of phosphorylated
p38 (P38-P) with phospho-tau in a subpopulation of neurons
and grains, suggesting the active participation of the kinase
in tau phosphorylation, is observed as well in AGD (Ferrer
et al., 2003, 2008) and in mice inoculated with AGD
sarkosyl-insoluble fractions.
Similar deposits are reported following brain inoculation of
AGD homogenates in WT mice with the exception of tau deposits
categorized as TSAs (Clavaguera et al., 2013a, 2015).
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FIGURE 7 | (A–D) WT mice unilaterally inoculated in the hippocampus with
sarkosyl-insoluble fractions from AGD at the age of 12 months and killed at
19 months (7 months survival) showing tau-immunofluorescent CA1 neurons
(asterisks) in the ipsilateral hippocampus (A), and deposits of
hyper-phosphorylated tau in the cytoplasm of oligodendrocytes (B,C; arrows)
as revealed with double-labeling immunofluorescence to NeuN (green) and
P-tauThr181 (red), and Olig2 (green) and AT8 (red), respectively.
Double-labeling immunofluorescence to phosphorylated p38 (p38-P,
p38-PThr180-182) (green) and AT8 (red) in WT mice inoculated with
sarkosyl-insoluble fractions from AGD at the age of 12 months and killed at
the age of 19 months (7 months survival) (D). Active p38 kinase (p38-P)
co-localizes with tau deposits in tau-positive grains (thick arrows) and threads
in the hippocampus. E: WT mouse unilaterally inoculated in the hippocampus
with sarkosyl-insoluble fractions from PART at the age of 12 months and killed
at 19 months (7 months survival) showing tau-immunofluorescent
oligodendrocyte (thin arrow) and threads (short arrows) in the contralateral
corpus callosum. Paraffin sections, nuclei stained with DRAQ5TM (blue); (A),
bar = 10 µm; (B), bar = 30 µm; (C,D), bar = 10 µm; (E) = 25 µm.
A major differential point between AGD and AGD-inoculated
mice is the presence of 3Rtau in addition to 4Rtau in tau-
bearing neurons, oligodendrocytes, threads, and grains in AGD-
inoculated mice. Since the AGD cases used for inoculation
do not contain 3Rtau deposits, and the western blotting
of sarkosyl-insoluble fractions shows a typical signature of
4Rtaupathy, the presence of 3Rtau implies the necessary
phosphorylation of murine 3Rtau, in addition to 4Rtau, in the
composition of abnormal tau deposits in mice inoculated with
AGD sarkosyl-insoluble fractions.
For comparative purposes, another series of mice was
inoculated with sarkosyl-insoluble fractions of PART, a primary
3R + 4Rtau neuronal-only tauopathy with NFTs in the temporal
lobes (Crary et al., 2014). PART has also been considered part
of AD without β-amyloid deposition and predominant early and
middle stages of NFT pathology according to the classification
of Braak and Braak of AD (Duyckaerts et al., 2015). Subtle
differences in NFT pathology between PART, and early and
middle stages of AD (Bell et al., 2019), are barely sufficient to
firmly categorize these conditions as unrelated diseases (Jellinger,
2019). Inoculation of sarkosyl-insoluble fractions of PART results
in the presence of 4Rtau and 3Rtau phospho-tau in neurons
in the hippocampus, and of oligodendrocytes and threads in
the corpus callosum three months after inoculation. Mice with
7 months of survival have an extension of tau deposits to
distant regions such as the hypothalamus, and nuclei of the
septum, and to the middle and contralateral corpus callosum,
in addition to greater extension along the anterior-posterior
axis when compared with mice inoculated with AGD at the
same survival times. Despite the small number of animals
used in the present study which precludes quantitative analysis,
differences between AGD and PART may be due to several factors
including different amounts of phospho-tau in the inoculums,
different species of tau (as seen looking at the tau species
in western blots of sarkosyl-insoluble fractions), and differing
capacity of “fibril” formation (as illustrated by the different
profiles of ThT amyloid quantification assay in vitro). Moreover,
we cannot obviate the possibility that AGD spreading is slower
than PART spreading as the longest survival time in both
settings is 7 months.
Major differential points between PART and PART-
inoculated mice are the presence of phospho-tau deposits
in oligodendrocytes in inoculated mice which are absent in
PART, and the lack of NFTs in mice in contrast with PART.
Identification of NFTs was made by comparing the compact
tangle morphology of tau deposits in PART neurons with the
granular characteristics of neuronal tau deposits in mice. Here
again, we cannot rule out the possibility that tangles in mice
need more time than the maximal 7-month period available in
the present study.
The present results are in line with the concept that abnormal
tau has the capacity to seed and spread following the intracerebral
inoculation of recombinant tau in transgenic mice expressing
P301S or P301L tau mutation (Iba et al., 2013; Peeraer et al.,
2015). Similarly, tau obtained from the brain of different human
tauopathies has the capacity to seed and spread in transgenic
mice expressing the longest human four-repeat tau isoform
(ALZ17 line) (Clavaguera et al., 2013a,b), or in transgenic mice
bearing the P301S tau mutation (line PS19) (Boluda et al.,
2015). Neurons, oligodendrocytes and astrocytes, with particular
features depending on the disease in question, are targets of
tau seeding and spreading in all these settings, pointing to
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the importance of different tau strains in tauopathies. These
observations are in agreement with other studies showing the
variability of tau deposits depending on tau strains in vitro and
in vivo (Sanders et al., 2014; Kaufman et al., 2016).
Pioneering inoculations of brain homogenates from human
tauopathies in WT mice showed a limited variety of tau
deposits in neurons and glial cells (Lasagna-Reeves et al., 2012;
Clavaguera et al., 2013b). In another study, neurons were
reported as the only targets of tau seeding and spreading
following inoculation of AD homogenates (Guo et al., 2016).
However, tau seeding and propagation in neurons, astrocytes
and oligodendrocytes was observed following inoculation of
paired helical filament (PHF)-enriched fractions from CBD and
PSP; deposits in astrocytes comparable to astrocytic plaques
were reported following inoculation of CBD, and doubtful
tufted astrocytes following inoculation of PSP homogenates
(Narasimhan et al., 2017). Finally, only grains, threads,
and coiled bodies with phosphorylated tau were produced
following inoculation of PHF-enriched fractions from AD in
the dentate gyrus of WT mice a survival time of 3 months
after inoculation (Audouard et al., 2016). These variations
demonstrate different profiles of tau spreading depending not
only on the disease but also on the methods and doses used
for inoculation.
Tau can be transmitted trans-synaptically from one neuron
to another neuron, based on connectivity rather than on
proximity, thus facilitating progression of tau pathology in
tauopathies (Liu et al., 2012; Ahmed et al., 2014; Dujardin
et al., 2014b; Lewis and Dickson, 2016; Goedert and Spillantini,
2017; Goedert et al., 2017; Mudher et al., 2017; Gibbons
et al., 2019). Tau secretion can also be produced by exo-
synaptic secretory mechanisms, including free release of tau to
the extracellular space, and vesicle-associated exocytosis. Free
release to the extracellular space is indeed the means used to
inoculate tau in the brain, and to make tau available to cultured
cells. The vesicular-mediated secretary pathways, represented by
microvesicles and exosomes, use the Endosomal Sorting Complex
Required for Transport (ESCRT) (Abels and Breakefield, 2016).
Microvesicles are generated by outward budding of the plasma
membrane, whereas exosomes are rich in lipid rafts, and they
are released upon depolarization of the plasma membrane
(DeLeo and Ikezu, 2018; van Niel et al., 2018; Ruan and
Ikezu, 2019). The two mechanisms may participate in tau
secretion in different settings (Saman et al., 2012; Dujardin et al.,
2014a; Lewis and Dickson, 2016; Goedert and Spillantini, 2017;
Wang et al., 2017; DeLeo and Ikezu, 2018; Guix et al., 2018;
Polanco et al., 2018; Ruan and Ikezu, 2019). Finally, tau can
be transmitted through tunneling nanotubes which are actin-
based nanotubular channels that connect one cell to another
(Rustom et al., 2004; Davis and Sowinski, 2008). Tau is a
component of nanotubes, and extracellular tau enhances the
formation of nanotubes, and facilitates the transfer of tau from
one cell to another (Tardivel et al., 2016). Tau uptake can be
achieved through various mechanisms, including endocytosis,
micropynocitosis, membrane fusion, and the activity of specific
receptors (Frost et al., 2009; Kfoury et al., 2012; Holmes
et al., 2013; Wu et al., 2013; Christianson and Belting, 2014;
Mulcahy et al., 2014; Calafate et al., 2016; Bolós et al., 2017;
Morozova et al., 2019).
Non-trans-synaptic transmission may be inferred as the
process of tau uptake by oligodendrocytes following tau
inoculation. Endogenous mouse tau is accumulated in
oligodendrocytes in mice expressing transgenic human
tau, thus indicating that mouse tau has the capacity to be
recruited and aggregated in oligodendrocytes (Ren et al., 2014).
Moreover, oligodendrocytes are the only cell targets, beside
threads, following inoculation of sarkosyl-insoluble fractions
from a wide variety of tauopathies in the corpus callosum
of WT mice (Ferrer et al., 2018, 2019, 2020a,b). Similarly,
human tau can be trapped by axons following inoculation.
Then tau can be transported along nerve fibers and, more
importantly, it can activate the phosphorylation of resident tau
through the activation of kinases. In support of this, previous
studies have shown that small misfolded tau is internalized
via endocytosis, and it is anterogradely and retrogradely
transported in neurons (Wu et al., 2013). Therefore, tau
uptake by oligodendrocytes and axonal fibers is likely linked to
endocytosis and micropynocitosis.
Differences between human AGD and AGD-inoculated
mice are the result of multiple factors. Among these, the
characteristics of tau are different in the two species. In adult
human brain, 4Rtau and 3Rtau species are balanced, whereas
in the adult mouse brain 4Rtau predominates. In addition
to differences in the shift of isoform expression linked to
exon 10 from embryonic to adult brain between murine and
human brain, murine tau also differs from human tau in
the N-terminal domain and three amino acid residues at the
C-terminal domain (Goedert et al., 1988; Lee et al., 1988;
Kampers et al., 1999; Goedert and Spillantini, 2019; Sayas
et al., 2019). This is an important point as the N-terminal
domain is crucial for specific protein-protein interactions
(Stefanoska et al., 2018).
Moreover, the distribution and localization of the different
tau isoforms in mice is region-dependent (Bullmann et al., 2007;
McMillan et al., 2008; Liu and Götz, 2013). These differences may
explain the distinct vulnerability and types of lesions between
human diseases and inoculated WT mice which express only
murine tau. Not only tau strains in the donor, but also tau
strains in the host are critical to the formation of characteristic
tau deposits. Moreover, differing cell vulnerability may depend
on the availability of tau in particular cell types. Neurons and
oligodendrocytes have a high capacity to recruit endogenous
tau to form tau aggregates following inoculation of tau from
different tauopathies; in contrast, the capacity of astrocytes is
more limited. ARTAG homogenates produce tau seeding and
spreading in neurons, oligodendrocytes and threads in WT mice,
but astrocytes are rather resistant to producing tau inclusions
following inoculation of ARTAG homogenates (Ferrer et al.,
2018) and homogenates from other tauopathies in WT mice
(Ferrer et al., 2019, 2020a,b), unless large amounts of tau are
inoculated (Narasimhan et al., 2017).
Finally, an intriguing aspect is the deposits of 3Rtau following
inoculation of sarkosyl-insoluble of AGD observed here and
in other pure 4Rtau tauopathies (Ferrer et al., 2018, 2020a,b).
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It may appear that 3Rtau aggregates in inoculated mice are
found in immature neurons which are recruited following the
administration of tau. However, 3Rtau is not only found in
neurons with mature appearance but also in oligodendrocytes
and along the fibers of very long tracts such as the corpus
callosum. In fact, little is known about the local machinery
put in motion after intake of abnormal tau to recruit and
actively phosphorylate local tau. Several regulatory elements exist
in the introns flanking exon 10 during normal development,
some upstream and others downstream, including inhibitors
such as SRp30c, SRp55, SRp75, 9G8, U2AF, PTB, and hnRNPG,
and activators such as htra2beta1, CELF3, and CELF4 (Gao
et al., 2000; Sobrido et al., 2003; Wang et al., 2004; Andreadis,
2005). Nothing is known about the role of these regulatory
factors following tau inoculation in murine models and in tau-
treated cultured cells.
These results show the capacity for seeding and spreading
of AGD tau in the brain of WT mice, and suggest that the
characteristics of donor tau and host tau underlie common
and specific aspects of deposits both in human disease
and corresponding experimentally induced murine models.
Understanding the mechanisms modulating tau recruitment and
modifications in the host needs further efforts.
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